{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T23:52:44Z","timestamp":1788652364255,"version":"build-2803163510"},"reference-count":79,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Avatrombopag, a second\u2010generation thrombopoietin receptor agonist (TPO\u2010RA), represents a significant advancement in the treatment of chronic immune thrombocytopenic purpura (cITP) and a potential therapeutic option for other thrombocytopenic disorders. Approved in both the USA and Europe, avatrombopag offers a convenient oral dosing regimen, initiated at 20\u2009mg daily with food, to achieve and maintain platelet counts \u2265\u200950\u2009\u00d7\u200910\n                    <jats:sup>9<\/jats:sup>\n                    \/L. Its favorable safety profile, characterized by minimal hepatic toxicity and the absence of dietary restrictions, distinguishes it from older TPO\u2010RAs such as eltrombopag and romiplostim. Clinical trials and real\u2010world data support its efficacy, with over 90% of patients that fail to standard first\u2010 and second\u2010line treatments or become unresponsive, achieving target platelet counts, and its hepatotoxicity\u2010free profile makes it particularly advantageous for patients with liver disease or complex comorbidities. Economic evaluations, including a budget impact analysis for the Italian National Health Service, have projected significant healthcare cost savings associated with avatrombopag use, reinforcing its value as a cost\u2010effective therapeutic option. However, challenges remain, including limited data on long\u2010term safety. In this review, we aim to provide a comprehensive synthesis of clinical evidence and real\u2010world data on avatrombopag's efficacy, safety, and pharmacological advantages, while exploring its current and potential therapeutic applications, such as chemotherapy\u2010induced thrombocytopenia and aplastic anemia.\n                  <\/jats:p>","DOI":"10.1111\/ejh.14395","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:43:21Z","timestamp":1738716201000},"page":"733-746","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Avatrombopag for the Treatment of Immune Thrombocytopenia"],"prefix":"10.1111","volume":"114","author":[{"given":"Caterina","family":"Labanca","sequence":"first","affiliation":[{"name":"Hematology Unit Azienda Ospedaliera Annunziata  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Vigna","sequence":"additional","affiliation":[{"name":"Hematology Unit Azienda Ospedaliera Annunziata  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica Antonia","family":"Martino","sequence":"additional","affiliation":[{"name":"Hematology Unit Azienda Ospedaliera Annunziata  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9456-2404","authenticated-orcid":false,"given":"Antonella","family":"Bruzzese","sequence":"additional","affiliation":[{"name":"Hematology Unit Azienda Ospedaliera Annunziata  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Mendicino","sequence":"additional","affiliation":[{"name":"Hematology Unit Azienda Ospedaliera Annunziata  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Carid\u00e0","sequence":"additional","affiliation":[{"name":"Hematology Unit Azienda Ospedaliera Annunziata  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Lucia","sequence":"additional","affiliation":[{"name":"Hematology Unit Azienda Ospedaliera Annunziata  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Olivito","sequence":"additional","affiliation":[{"name":"Hematology Unit Azienda Ospedaliera Annunziata  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Puccio","sequence":"additional","affiliation":[{"name":"Laboratorio di Ricerca Traslazionale Azienda USL\u2010IRCSS Reggio Emilia  Reggio Emilia Emilia\u2010Romagna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Neri","sequence":"additional","affiliation":[{"name":"Scientific Directorate IRCCS of Reggio Emilia  Reggio Emilia Emilia\u2011Romagna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2585-7073","authenticated-orcid":false,"given":"Fortunato","family":"Morabito","sequence":"additional","affiliation":[{"name":"Gruppo Amici Dell'Ematologia Foundation\u2010GrADE  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[{"name":"Hematology Unit Azienda Ospedaliera Annunziata  Cosenza Italy"},{"name":"Department of Pharmacy, Health and Nutritional Science University of Calabria  Rende Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.12214"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2013.03.001"},{"issue":"1","key":"e_1_2_11_4_1","first-page":"237","article-title":"Bleeding Complications in Immune Thrombocytopenia","volume":"2015","author":"Arnold D. M.","year":"2015","journal-title":"Hematology 2014, the American Society of Hematology Education Program Book"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1810479"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21616"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222010918"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13803"},{"issue":"21","key":"e_1_2_11_9_1","first-page":"2829","article-title":"Clinical Updates in Adult Immune Thrombocytopenia","volume":"129","author":"Lambert M. P.","year":"2017","journal-title":"Blood, the Journal of the American Society of Hematology"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2008.12.005"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e32833eaef3"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103820"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000812"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000966"},{"issue":"11","key":"e_1_2_11_15_1","first-page":"2386","article-title":"Standardization of Terminology, Definitions and Outcome Criteria in Immune Thrombocytopenic purpura of Adults and Children: Report From an International Working Group","volume":"113","author":"Rodeghiero F.","year":"2009","journal-title":"Blood, the Journal of the American Society of Hematology"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.400"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010975"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2005.00602.x"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000205503"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-013-1382-0"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.23.11104"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/369533a0"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90450-2"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/369565a0"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jbchem.a124883"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.2.651"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24702"},{"issue":"11","key":"e_1_2_11_28_1","first-page":"4607","article-title":"New Thrombopoietic Growth Factors","volume":"109","author":"Kuter D. J.","year":"2007","journal-title":"Blood, the Journal of the American Society of Hematology"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.7.2599"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00056.x"},{"key":"e_1_2_11_31_1","unstructured":"Amgen Inc \u201cNPLATE: Prescribing Information \u201daccessed October 29 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125268s163lbl.pdf."},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.276.5319.1696"},{"key":"e_1_2_11_33_1","unstructured":"DrugBank Online \u201cRomiplostim \u201d2024accessed October 2024 https:\/\/go.drugbank.com\/drugs\/DB05332."},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.05975.x"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2003.05.001"},{"key":"e_1_2_11_36_1","unstructured":"European Medicines Agency (EMA) \u201cNplate \u2010 Product Information \u201d2024accessed November 02 2024 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/nplate\u2010epar\u2010productinformation_en.pdf."},{"key":"e_1_2_11_37_1","unstructured":"European Medicines Agency (EMA) \u201cRevolade \u2010 Product Information \u201d2024accessed November 02 2024 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/revolade\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_11_38_1","unstructured":"European Medicines Agency (EMA) \u201cDoptlet \u2010 product Information.\u201d"},{"key":"e_1_2_11_39_1","unstructured":"Dova Pharmaceuticals Inc \u201cDoptelet: Prescribing Information \u201daccessed on October 29 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/210238s001lbl.pdf2019."},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V112.11.5391.5391"},{"key":"e_1_2_11_41_1","unstructured":"GlaxoSmithKline \u201cPromacta: Prescribing Information \u201d2024accessed on November 1 2024 www.novartis.us\/files\/promacta.pdf."},{"key":"e_1_2_11_42_1","unstructured":"Shionogi Inc \u201cMulpleta: Prescribing Information \u201d2021.accessed on November 1 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210923s000lbl.pdf."},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S191790"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12815"},{"key":"e_1_2_11_45_1","doi-asserted-by":"crossref","unstructured":"R. E.Desjardins D. L.Tempel R.Lucek et\u00a0al. \u201cSingle and Multiple Oral Doses of AKR\u2010501 (YM477) Increase the Platelet Count in Healthy Volunteers.\u201d","DOI":"10.1182\/blood.V108.11.477.477"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2008.04.020"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2008.01198.x"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13517"},{"key":"e_1_2_11_49_1","unstructured":"Swedish Orphan Biovitrum \u201cDoptelet (Avatrombopag): EU Summary of Product Characteristics \u201d2021 https:\/\/www.ema.europa.eu\/."},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1267"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14295"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15574"},{"issue":"25","key":"e_1_2_11_53_1","first-page":"3887","article-title":"A Randomized Trial of Avatrombopag, an Investigational Thrombopoietin\u2010Receptor Agonist, in Persistent and Chronic Immune Thrombocytopenia","volume":"123","author":"Bussel J. B.","year":"2014","journal-title":"Blood, the Journal of the American Society of Hematology"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15573"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.00"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2021.1881952"},{"key":"e_1_2_11_57_1","article-title":"Avatrombopag Treatment Response in Patients With Immune Thrombocytopenia: The REAL\u2010AVA 1.0 Study. Therapeutic","volume":"14","author":"Oladapo A.","year":"2023","journal-title":"Advances in Hematology"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27498"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18081"},{"key":"e_1_2_11_60_1","unstructured":"\u201cSobi Announces FDA Acceptance of New Drug Application for Avatrombopag (DOPTELET) for the Treatment of Pediatric Immune Thrombocytopenia. Press release. Sobi. December 12 2024 \u201daccessed December 16 2024 https:\/\/tinyurl.com\/2p8mtys92024."},{"key":"e_1_2_11_61_1","article-title":"A Phase 3, Randomised, Double\u2010Blind, Placebo\u2010Controlled Trial to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Children With Chronic Immune Thrombocytopenia (AVA\u2010PED\u2010301)","author":"Grace R. F.","year":"2024","journal-title":"European Hematology Association Congress"},{"key":"e_1_2_11_62_1","volume-title":"Poster Presented at: International Society on Thrombosis and Haemostasis (ISTH)","author":"Bussel J.","year":"2019"},{"key":"e_1_2_11_63_1","unstructured":"Center for Drug Evaluation and Research \u201cNDA Application Number 210238 \u201dhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210238Orig1s000MultidisciplineR.pdf."},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62129-5"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00829"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100125"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18908"},{"key":"e_1_2_11_68_1","unstructured":"Centers for Disease Control and Prevention \u201cChronic Liver Disease and Cirrhosis \u201d2024accessed November 26 2024 https:\/\/www.cdc.gov\/nchs\/fastats\/liver\u2010disease.htm."},{"key":"e_1_2_11_69_1","first-page":"155","article-title":"Current Management of Thrombocytopenia in Chronic Liver Disease Gastroenterol","volume":"15","author":"Brown R. S.","year":"2019","journal-title":"Hepatology"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12605"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.05.025"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035208"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.970978"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1253230"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2224044"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2022.11.002"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2023.12092"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2023.2253069"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2023.2267942"},{"key":"e_1_2_11_80_1","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2021.1978689"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T12:08:15Z","timestamp":1754914095000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":79,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1111\/ejh.14395"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14395","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"2024-12-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}